This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by Boston Scientific, the manufacturer of the WATCHMAN device.
Reference
Reddy VY, et al. Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared With Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation. Stroke : 8 May 2018. Available from: URL: http://doi.org/10.1161/STROKEAHA.117.018825
Rights and permissions
About this article
Cite this article
Left atrial appendage closure cost effective in stroke prevention in AF. PharmacoEcon Outcomes News 803, 16 (2018). https://doi.org/10.1007/s40274-018-4943-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4943-x